AU2013231052B2 — Crystalline forms of n-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-n-((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-l-prolinamide
Assigned to Bristol Myers Squibb Holdings Ireland ULC · Expires 2015-09-10 · 11y expired
What this patent protects
Abstract The present disclosure generally relates to crystalline forms ofN-(tert butoxycarbonyl)-3 -methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy- 1 isoquinolinyl)oxy)-N-((l R,2S)- 1 -((cyclopropylsulfonyl)carbamoyl)-2 vinylcyclopropyl)-L-prolinamide. The present disclosure also gen…
USPTO Abstract
Abstract The present disclosure generally relates to crystalline forms ofN-(tert butoxycarbonyl)-3 -methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy- 1 isoquinolinyl)oxy)-N-((l R,2S)- 1 -((cyclopropylsulfonyl)carbamoyl)-2 vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well as methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.